[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-340814-105":59,"doc-detail-340814-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","kras-inhibitors-resistance-drivers-and-combinatorial-strategies","KRAS inhibitors - resistance drivers and combinatorial strategies","","KRAS inhibitors journeyed from the early discovery of RAS oncogenes to clinically effective therapy after decades of difficulty in targeting RAS proteins. Following the 2013 identification of a druggable KRAS pocket, covalently binding KRASG12C inhibitors entered FDA approval in 2021 and 2022. This review emphasizes resistance mechanisms and outlines combinatorial treatment strategies that improve patient responses, addressing why landmark progress also introduced new hurdles for RAS drug discovery.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/kras-inhibitors-resistance-drivers-and-combinatorial-strategies/340814/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/kras-inhibitors-resistance-drivers-and-combinatorial-strategies/340814.png","ImageObject",300,407,{"name":92,"@type":93},"Ophelia","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why was KRAS long considered difficult to target with small-molecule inhibitors?","Question",{"text":112,"@type":113},"KRAS lacks deep hydrophobic pockets on its surface and binds GTP with exceptionally high affinity, while cellular GTP concentration is high. These factors make selective inhibition far more challenging than kinase targeting.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What enabled the development of clinically effective KRASG12C inhibitors?",{"text":117,"@type":113},"In 2013, a druggable pocket in KRAS was identified by Shokat and colleagues, enabling covalently binding KRASG12C inhibitors. FDA approval followed in 2021 and 2022 for sotorasib and adagrasib.",{"name":119,"@type":110,"acceptedAnswer":120},"What is the focus of this review regarding KRAS therapy?",{"text":121,"@type":113},"The review highlights progress in defining resistance mechanisms and developing combination treatment strategies to improve patient responses to KRAS-directed therapies.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},340814,1790335491,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},7971461741311,"https://ap-avatar.wpscdn.com/avatar/74000253aff267980c6?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779345379180704826","Author Manuscr ipt Author Manuscr ipt Author Manuscr ipt Author Manuscript  \n\n| | HHS Public Access\u003Cbr>Author manuscript\u003Cbr>Trends Cancer. Author manuscript; available in PMC 2026 June 26. |\n| --- | --- |\n\nPublished in final edited form as:  \nTrends Cancer. 2025 February ; 11(2): 91–116. doi:10.1016/j.trecan.2024.11.009 .  \nKRAS inhibitors: resistance drivers and combinatorial strategies  \nTamara Isermann 1,2 , Christine Sers 1,2 , Channing J. Der1,3,4 , Bjoern Papke 1,2,3,4,*  \n1Charité – Universitätsmedizin Berlin, Institute of Pathology, Berlin, Germany  \n2German Cancer Consortium (DKTK), Partner Site Berlin, German Cancer Research Center (DKFZ), Heidelberg, Germany  \n3Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA  \n4 Department of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA  \nAbstract  \nIn 1982, the RAS genes HRASand KRAS were discovered as the first human cancer genes, with KRAS later identified as one of the most frequently mutated oncogenes. Yet, it took nearly 40 years to develop clinically effective inhibitors for RAS-mutant cancers. The discovery in 2013 by Shokat and colleagues of a druggable pocket in KRAS paved the way to FDA approval of the first covalently binding KRASG12C inhibitors, sotorasib and adagrasib, in 2021 and 2022, respectively.  \nHowever, rather than marking the end of a successful assault on the Mount Everest of cancer research, this landmark only revealed new challenges in RAS drug discovery. In this review, we highlight the progress on defining resistance mechanisms and developing combination treatment strategies to improve patient responses to KRAS therapies.  \nThe rise of RAS oncogenes as undruggable cancer targets  \nThe year 1982 marked the beginning of a new era in cancer research, with the discovery of HRAS and KRAS as the first human cancer genes [1,2] . Since then, the RAS gene family, comprising HRAS, NRAS, and KRAS, has been identified as one of the most important oncogene groups in cancer [3,4]. Among all RAS genes, KRASis the most frequently mutated, accounting for ~80% of all RAS mutations [5,6]. Notably, RAS mutations exhibit significant tissue specificity, with the most common and lethal cancer types, such as colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC), and non-small cell lung cancer (NSCLC), being prominently associated with KRAS mutations (43%, 85%, and 31%, respectively) (Figure 1A) [7]. By contrast, HRAS mutations are commonly linked to skin cancer (excluding melanoma) (6%), bladder cancer (5%), and head and neck cancer (7%), while NRAS mutations are prominent in melanoma (23%), thyroid cancer (11%), and leukemia (9%) i (Figure 1B) . RAS proteins are key regulators of oncogenic signaling  \nThis is an open access article under the CC BY license ([http://creativecommons.org/licenses/by/4.0/](http://creativecommons.org/licenses/by/4.0/)).  \n*Correspondence: Bjoern.Papke@charite.de (B. Papke) .  \n[i](i www.synapse.org/Synapse:syn52433756)[ www.synapse.org/Synapse:syn52433756](i www.synapse.org/Synapse:syn52433756)  \nAuthor Manuscr ipt Author Manuscr ipt Author Manuscr ipt Author Manuscript  \nIsermann et al. Page 2  \npathways, including mitogen-activated protein kinase (MAPK) and phosphoinositide 3-kinase (PI3K) pathways. This is further underscored by the high frequency of cancer-driving mutations in RAS downstream effectors (Box 1), including oncoproteins, such as BRAF (8%), AKT1/2 (4%), MEK1/2 (2%), and PIK3CA (13%) i, which all result in constitutive protein activity promoting tumor growth and survival. The important role of RAS proteins and RAS downstream effectors as drivers of cancer has led to an intense search for effective RAS inhibitors.  \nEarly on, experimental studies using cell culture and mouse models confirmed mutant RAS as a critical driver of cancer development and progression, further validating it as a favorable cancer target [8,9]. Howe","cbCaimfDimxo3uI9","https://ap.wps.com/l/cbCaimfDimxo3uI9","pdf",2190463,39,"English","# Abstract\n# The rise of RAS oncogenes as undruggable cancer targets\n## RAS proteins are key regulators of oncogenic signaling\n## Early strategies for targeting RAS\n# Review scope and clinical progress","[{\"question\":\"Why was KRAS long considered difficult to target with small-molecule inhibitors?\",\"answer\":\"KRAS lacks deep hydrophobic pockets on its surface and binds GTP with exceptionally high affinity, while cellular GTP concentration is high. These factors make selective inhibition far more challenging than kinase targeting.\"},{\"question\":\"What enabled the development of clinically effective KRASG12C inhibitors?\",\"answer\":\"In 2013, a druggable pocket in KRAS was identified by Shokat and colleagues, enabling covalently binding KRASG12C inhibitors. FDA approval followed in 2021 and 2022 for sotorasib and adagrasib.\"},{\"question\":\"What is the focus of this review regarding KRAS therapy?\",\"answer\":\"The review highlights progress in defining resistance mechanisms and developing combination treatment strategies to improve patient responses to KRAS-directed therapies.\"}]","KRAS inhibitors - resistance drivers and combinatorial strategies | PDF",1790038977,98,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e35c9c6039f6b87ec2d2bf9b7626253c.webp",983,1272,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/86d17c2ff1293d68992f4e48d80bfe83.webp",982,1270,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6298b04442994051a71c0efbc8aaf073.webp",981,1269,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e6cf8923a34de9825f7b162c1c7ea32a.webp",980,1268]